A new analysis of recently introduced pharmaceuticals found that the median list price of a drug at launch increased 24% a year between 2022 and 2024, adjusted for inflation, while the net price, taking into account rebates and discounts, rose a stunning 51% a year, far outpacing inflation.
ICER said gene and cell therapies, orphan drugs, first-in-class drugs, cancer treatments, and endocrine drugs were all associated with higher launch prices.
The Trump administration, and before that President Biden, made bringing down high drug prices a key initiative. Under President Biden’s Inflation Reduction Act of 2022, Medicare is empowered to negotiate drugs prices for the first time, and pharmaceutical companies are penalized for increasing the price of certain drugs faster than the inflation rate.
President Trump plans to launch TrumpRx in 2026, a direct to consumer drug portal, that is meant to offer lower prices, and has demanded that drug makers bring down the prices of prescription drugs in the U.S. to match the lowest price offered in other developed nations — known as the most-favored-nation price.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
